Three-Pronged attack tested against Tough-to-Treat uterine cancer
NCT ID NCT03694262
Summary
This study tested a combination of three existing drugs (rucaparib, bevacizumab, and atezolizumab) for women with recurrent or progressive endometrial cancer that had stopped responding to prior treatment. The goal was to see if using these drugs together could shrink tumors and control the disease better than previous options. Researchers enrolled 30 participants to measure how well the tumors responded and to monitor the safety of this combination therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
-
Mount Sinai
New York, New York, 10029, United States
-
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, 18015, United States
Conditions
Explore the condition pages connected to this study.